ECSP088906A - PIRAZOLO 1,5-a PIRIMIDINAS - Google Patents
PIRAZOLO 1,5-a PIRIMIDINASInfo
- Publication number
- ECSP088906A ECSP088906A EC2008008906A ECSP088906A ECSP088906A EC SP088906 A ECSP088906 A EC SP088906A EC 2008008906 A EC2008008906 A EC 2008008906A EC SP088906 A ECSP088906 A EC SP088906A EC SP088906 A ECSP088906 A EC SP088906A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- cdks
- pirazolo
- pyrimidins
- cyclin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En sus muchas realizaciones, la presente invención provee ciertos compuestos de pirazolo[1,5-a]pirimidina los cuales pueden tener utilidad como inhibidores de las quinasas dependientes de ciclina ("CDKs", según sus siglas en inglés) así como también métodos para la preparación de tales compuestos. Los compuestos pueden tener potencial utilidad para el tratamiento, prevención, inhibición o mejora de una o más enfermedades asociadas con las CDKs.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80257706P | 2006-05-22 | 2006-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088906A true ECSP088906A (es) | 2008-12-30 |
Family
ID=38544151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008906A ECSP088906A (es) | 2006-05-22 | 2008-11-21 | PIRAZOLO 1,5-a PIRIMIDINAS |
Country Status (18)
Country | Link |
---|---|
US (1) | US20070275963A1 (es) |
EP (1) | EP2027127A1 (es) |
JP (1) | JP2009538304A (es) |
KR (1) | KR20090019796A (es) |
CN (1) | CN101495481A (es) |
AR (1) | AR061072A1 (es) |
AU (1) | AU2007268083A1 (es) |
BR (1) | BRPI0712016A2 (es) |
CA (1) | CA2653076A1 (es) |
EC (1) | ECSP088906A (es) |
IL (1) | IL195238A0 (es) |
MX (1) | MX2008014824A (es) |
NO (1) | NO20085331L (es) |
PE (1) | PE20080071A1 (es) |
RU (1) | RU2008150419A (es) |
TW (1) | TW200817404A (es) |
WO (1) | WO2007139732A1 (es) |
ZA (1) | ZA200809796B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8603998B2 (en) * | 2007-11-07 | 2013-12-10 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
SG179083A1 (en) * | 2009-09-11 | 2012-04-27 | Cylene Pharmaceuticals Inc | Pharmaceutically useful heterocycle-substituted lactams |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
CA2833288A1 (en) * | 2011-04-19 | 2012-10-26 | Bayer Intellectual Property Gmbh | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | C−jun−n−末端キナーゼ(jnk)の阻害剤 |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
ES2842876T3 (es) | 2012-12-07 | 2021-07-15 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer |
EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
ES2768678T3 (es) | 2013-12-06 | 2020-06-23 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas |
EP3084008B1 (en) | 2013-12-17 | 2018-07-18 | Csir | A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds |
LT3152212T (lt) | 2014-06-05 | 2020-05-11 | Vertex Pharmaceuticals Inc. | Radioaktyviai žymėti 2-amino-6-fluor-n-[5-fluor-piridin-il]- pirazolo[1,5-a]pirimidin-3-karboksamido junginio dariniai, naudingi kaip atr kinazės inhibitoriai, minėto junginio gamybos būdas ir jo skirtingos kietos formos |
US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
WO2016061144A1 (en) | 2014-10-14 | 2016-04-21 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
RU2633032C1 (ru) * | 2016-05-23 | 2017-10-12 | Общество с ограниченной ответственностью "Новые научные технологии" | Новые ингибиторы серин-треониновых киназ, в том числе для лечения онкологических заболеваний и туберкулеза |
CN111566100B (zh) * | 2018-02-12 | 2023-10-27 | 恩瑞生物医药科技(上海)有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
US11155560B2 (en) | 2018-10-30 | 2021-10-26 | Kronos Bio, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity |
CN111393447B (zh) * | 2020-05-14 | 2021-01-15 | 苏州信诺维医药科技有限公司 | 一种嘧啶并吡唑类化合物、其制备方法及应用 |
CN117567460A (zh) * | 2022-08-08 | 2024-02-20 | 明慧医药(杭州)有限公司 | 一种前药化合物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ539161A (en) * | 2002-09-04 | 2006-05-26 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
DK1537116T3 (da) * | 2002-09-04 | 2010-09-27 | Schering Corp | Pyrazolopyrimidiner egnede til behandling af cancersygdomme |
US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
CA2627623C (en) * | 2005-10-06 | 2014-04-22 | Schering Corporation | Methods for inhibiting protein kinases |
BRPI0617150A2 (pt) * | 2005-10-06 | 2011-07-12 | Schering Corp | pirazolopirimidinas como inibidores de protéina cinase |
-
2007
- 2007-05-21 EP EP07795066A patent/EP2027127A1/en not_active Withdrawn
- 2007-05-21 CN CNA2007800280091A patent/CN101495481A/zh active Pending
- 2007-05-21 PE PE2007000617A patent/PE20080071A1/es not_active Application Discontinuation
- 2007-05-21 KR KR1020087028392A patent/KR20090019796A/ko not_active Application Discontinuation
- 2007-05-21 BR BRPI0712016-8A patent/BRPI0712016A2/pt not_active IP Right Cessation
- 2007-05-21 JP JP2009512064A patent/JP2009538304A/ja active Pending
- 2007-05-21 AU AU2007268083A patent/AU2007268083A1/en not_active Abandoned
- 2007-05-21 RU RU2008150419/04A patent/RU2008150419A/ru not_active Application Discontinuation
- 2007-05-21 CA CA002653076A patent/CA2653076A1/en not_active Abandoned
- 2007-05-21 WO PCT/US2007/011991 patent/WO2007139732A1/en active Application Filing
- 2007-05-21 MX MX2008014824A patent/MX2008014824A/es unknown
- 2007-05-21 US US11/751,282 patent/US20070275963A1/en not_active Abandoned
- 2007-05-22 TW TW096118244A patent/TW200817404A/zh unknown
- 2007-05-22 AR ARP070102207A patent/AR061072A1/es not_active Application Discontinuation
-
2008
- 2008-11-11 IL IL195238A patent/IL195238A0/en unknown
- 2008-11-17 ZA ZA200809796A patent/ZA200809796B/xx unknown
- 2008-11-21 EC EC2008008906A patent/ECSP088906A/es unknown
- 2008-12-19 NO NO20085331A patent/NO20085331L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20085331L (no) | 2009-02-19 |
AR061072A1 (es) | 2008-07-30 |
IL195238A0 (en) | 2009-08-03 |
PE20080071A1 (es) | 2008-02-11 |
TW200817404A (en) | 2008-04-16 |
BRPI0712016A2 (pt) | 2011-12-27 |
RU2008150419A (ru) | 2010-09-20 |
US20070275963A1 (en) | 2007-11-29 |
WO2007139732A1 (en) | 2007-12-06 |
JP2009538304A (ja) | 2009-11-05 |
AU2007268083A1 (en) | 2007-12-06 |
ZA200809796B (en) | 2009-11-25 |
MX2008014824A (es) | 2008-12-01 |
CA2653076A1 (en) | 2007-12-06 |
CN101495481A (zh) | 2009-07-29 |
KR20090019796A (ko) | 2009-02-25 |
EP2027127A1 (en) | 2009-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088906A (es) | PIRAZOLO 1,5-a PIRIMIDINAS | |
ECSP088345A (es) | Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
MX2009011355A (es) | Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. | |
MX364157B (es) | Compuestos de pirazolo [1,5-a] pirimidina sustituidos como inhibidores de trk cinasa. | |
MY169791A (en) | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors | |
MX2009013729A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
CL2009001212A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras. | |
GT201000082A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
ZA200707342B (en) | Pyrrolopyrimidines useful as inhibitors of protein kinase | |
CL2011002956A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos. | |
MY188335A (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
DE602006014848D1 (de) | Pyrazolopyrimidine als inhibitoren von cyclinabhän | |
ME01269B (me) | Jedinjenja pirolo (2,3-d) pirimidina | |
MX2009012066A (es) | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
GEP20125368B (en) | Kinase inhibitors | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
TW200745127A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
MX2009003733A (es) | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. | |
MX2010005950A (es) | 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa. | |
EA201001242A1 (ru) | ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ | |
MX2009003734A (es) | Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina. |